What's breaking now, across thousands of outlets.
Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04710-1 In the phase 2 UNICORN trial, a short course of neoadjuvant botensilimab and balstilimab achieved the primary endpoint of pathological major response rate in patients with pMMR or dMMR colon cancer.
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
The Lagos State Government has said it has begun procuring antiretroviral drugs with state funds to sustain HIV treatment, noting that 147,904 people living with the virus receive medication across…
KUALA LUMPUR, Nov 2 (Bernama) -- The Dewan Rakyat sitting today will look into the status of the rare earth element (REE) industry policy, updates on obesity and diabetes treatment involving GLP-1 RA…
Feeling fatigued, less energetic, craving heavy foods? It could be a sign of the depressive disorder
Tuesday’s US midterm election is both hugely consequential and not so consequential even as the world waits to see the American voters’ verdict on Donald Trump’s presidency – and the impact that…
ISLAMABAD: A senior citizen taxpayer deriving income from bahbood/pensioner certificate was declared “In-Active” on November 1, 2026 by the Federal Board of Revenue (FBR) forcing the taxpayer to…
A transparent character can look correct in an image viewer yet acquire a dark fringe in a game. Before changing the artwork, check whether the image data and renderer agree about alpha representation…
